Table 1.
Characteristics of study populations in LSC and PLuSS*
| Characteristic | LSC (stage 1) | PLuSS (stage 2) |
|---|---|---|
| n | 1163 | 718 |
| Age, y, mean ± SD | 57.0±9.5 | 64.6±5.1 |
| Sex, male, % | 23.6 | 32.6 |
| Current smokers, % | 54.7 | 59.1 |
| Pack-years, mean ± SD | 41.6±21.4 | 55.1±20.7 |
| 10 – 30, % | 35.1 | 9.3 |
| 30 – 45, % | 32.0 | 22.6 |
| 45 – 166, % | 32.9 | 68.1 |
| Methylation prevalence, % | ||
| P16 | 20.7 | 15.6 |
| MGMT | 25.5 | 23.0 |
| DAPK | 14.5 | 13.0 |
| RASSF1A | 1.0 | 0 |
| GATA4 | 34.8 | 32.7 |
| GATA5 | 14.5 | 10.0 |
| PAX5α | 14.5 | 10.7 |
| PAX5β | 7.7 | 5.3 |
| SULF2 | 33.2 | 26.9 |
| PCDH20 | 35.1 | 24.7 |
| DAL1 | 6.8 | 5.7 |
| JPH3 | 23.0 | 7.0 |
| Pulmonary disorders, % | ||
| Chronic obstructive pulmonary disease | 32.7 | 44.6 |
| Chronic mucous hyper-secretion | 30.9 | 26.0 |
* LSC = the Lovelace Smokers Cohort; PLuSS = the Pittsburgh Lung Screening Study cohort; SD = standard deviation.